862647-12-9

Upstream product

• 862647-09-4 (2R)-2-benzhydryloxirane 
• 1826-67-1 vinyl magnesium bromide 
• 862647-11-8 (2S)-3,3-diphenylpropane-1,2-diol 
• 4646-55-3 N,N-dimethyl-3,3-diphenylpropan-1-amine 
• 101-81-5 Diphenylmethane 
• 15701-83-4 1,1-diphenyl-2,3-epoxy-propan 
• 3542-14-1 3,3-diphenylpropene 
• 947-91-1 Diphenylacetaldehyde 

Downstream Products

• 862647-14-1 (S)-(2-(allyloxy)pent-4-ene-1,1-diyl)dibenzene 
• 1332886-85-7 (2S,4R,5R)-2-benzhydryl-5-bromotetrahydro-2H-pyran-4-ol 
• 862647-18-5 (1S,4S,6R)-4-benzhydryl-3,7-dioxabicyclo[4.1.0]heptane 
• 862647-19-6 (1R,4S,6S)-4-benzhydryl-3,7-dioxabicyclo[4.1.0]heptane 
• 862647-16-3 (2S)-2-benzhydryl-3,6-dihydro-2H-pyran 

Relevant academic research and scientific papers

Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model

In this study we have generated a pharmacophore model of triple uptake inhibitor compounds based on novel asymmetric pyran derivatives and the newly developed asymmetric furan derivatives. The model revealed features important for inhibitors to exhibit a

An improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H- pyran-4-ol (D-142)

Triple monoamine reuptake inhibitors have been implicated in the development of a new generation of antidepressants with higher efficacy than the currently existing therapies. In this paper, we have developed an alternative efficient synthetic route for triple monoamine reuptake inhibitor D-142 in 18.5% overall yield in 11 steps starting from diphenylmethane. D-142 was developed by us recently. The key step of the present synthetic strategy is the preferential formation of a bromohydrin from olefin via a cis-bromonium intermediate, which introduced significant efficiency in the overall synthesis. Furthermore, we have developed an efficient way to recycle the optically active intermediate diol back to the desired chiral epoxide.

Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner

In our structure-activity relationship study on 3,6-disubstituted pyran derivatives, we have carried out asymmetric synthesis and biological characterization of trisubstituted (2S,4R,5R)-2-benzhydryl-5- benzylaminotetrahydropyran-4-ol and (3S,4R,6S)-6-ben

TRI-SUBSTITUED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES

Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti- depressants.